July 11, 2022
To Whom It May Concern

Genomic Medicine x AI Startup Xcoo,Inc.
raised a total of 700 million yen.
Xcoo, Inc (Headquarters : Bunkyo-ku, Tokyo / CEO Founder : Kunihiro Nishimura, PhD), which develops Chrovis, atotal solution software for genome and bioinformatic data analysis, and provides services related to the software,announces that it has raised a total of 700 million yen from SPARX Group Co., Ltd. as the lead investor and another company.
Background and Purpose of the Fundraising
Since its establishment in April 2011, Xcoo has focused on genomic medicine. Xcoo has contributed to the social
implementation of precision medicine, utilyzing its advanced computing technology, aiming for a world where
the most appropriate treatments are provided to each patient. Taking advantage of our proprietary product,
Chrovis, our team with prominent engineering skills and expertise in bioinformatics analyzes genome and omics
data for cancer diagnosis, treatment, and prevention, as well as for cutting-edge research and development.
We are also now focused on “clinical-annotation,” which adds clinically useful information to the sequenced
genome data. The cancer panel test, which is now becoming prevalent across Japan, is an innovative testing
method that could help ﬁnd the most suitable molecular-targeted drugs / treatments for the characteristics of thegenomic changes of the malignant tumor of each respective patient. However, a major challenge is the signiﬁcantamount of time and effort required to interpret and report the test results. We utilize information technology toautomatically process vast amounts of data across multiple databases, thereby supporting physiciansʼ decision
making in diagnosis / treatments based on test results and providing useful information to patients.
Three years have passed since the Comprehensive Genome Proﬁling (CGP) test was covered by Japanʼs publichealth insurance, and the cancer-genome-medicine related market continues to grow steadily with the annual
number of cases tested under the public insurance exceeding 10,000.

In light of this situation, we will further

accelerate the expansion and development of Chrovisʼ functions and services to meet the growing needs on theclinical front lines.

The funds raised will be invested mainly in human resources to strengthen our team for thisaim.
Comment from the lead investor
SPARX Group Co., Ltd.
Group Executive Ofﬁcer : Shigeki Sakuraba, MD, MPH, PhD
With the decline in the genomic analysis costs driven by the next-generation sequencers as well as national
policies in various countries to promote cancer genome medicine, we believe that this market will inevitably
expand in the future. For the quantitative and qualitative expansion of the cancer genome medicine market, it isimportant to create an environment in which physicians involved can concentrate on their unique role up to theﬁnal judgement of the diagnosis and the treatment policy. Chrovis provides a one-stop service from informationcollection and clinical annotation to reporting to patients, which can streamline physiciansʼ work, and will
become an indispensable tool for the cancer genome medicine practice in the future. As an investor, we are very
pleased to support the development of these innovative services across Japan and globally.

July 11, 2022
To Whom It May Concern

About Xcoo
A venture company orignating from the University of Tokyo, specialized in genome analysis and bioinformatics.
Xcoo has been developing and operating Chrovis, a total solution for genomic and bioinformatics analyses,
employing its advanced technology and development capabilities. Xcoo has received numerous startup-related
awards, including the MEXT Ministerʼs Award at Adcademic Startups 2019.
Headquarters： Headquarters : 2-40-8, Hongo, Bunkyo-ku, Tokyo 113-0033 JAPAN
CEO： Kunihiro Nishimura, Ph.D.
Established： April, 2011
Web site： https://xcoo.co.jp/
Xcooʼs Business： ・Development and operation of Chrovis, a total solution for genome and bioinformatics
analysis・Development of systems for high-speed data processing by parallel and distributedcomputing
・Development of systems for data analysis/visualization based on state-of-the-art algorithms
Recruitment information
We, Xcoo, are recruiting engineers and other professionals in order to realize our mission of bridging information
technology toward social implementation, thereby contributing to healthcare. For this purpose, we have ourbusiness concept of "organizing and analyzing large volumes of complex information (data intelligence), presenting them in easy-to-understand manners to people (visualization), and leading to actions (decision-making). We
welcome those who could share our mission and are willing to take on challenges together with our highly-skilled
engineers and other professional staff.
Web site： https://xcoo.co.jp/recruit.html

Contact us
PR Team： pr@xcoo.jp